Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.
INSIGHT-HER2BC: Real-world evidence of TCHP regimen to describe the best patient profile and open up questions—The interim results. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I ...
Results of two Chinese phase 3 trials presented at this year’s San Antonio Breast Cancer Symposium (SABCS) 2025 provide strong support for adjuvant carboplatin in early-stage triple-negative breast ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 ...
Singapore, 15 April 2026 – A global, multicentre phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National Cancer Centre Singapore, has demonstrated a ...
Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...
HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ...
Trodelvy showed fewer severe side effects, such as neutropenia and diarrhea, compared to chemotherapy in untreated TNBC patients. The study's primary endpoint, progression-free survival, favored ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results